<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00463749</url>
  </required_header>
  <id_info>
    <org_study_id>1111/2006</org_study_id>
    <nct_id>NCT00463749</nct_id>
  </id_info>
  <brief_title>Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein</brief_title>
  <acronym>LIPSIA-N-ACC</acronym>
  <official_title>Trial to Compare Infarct Size and Occurrence of Contrast Dye Induced Nephropathy in Patients With Primary Percutaneous PCI in STEMI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acetylcystein is a potent antioxidans which is able to prevent contrast dye induced
      nephropathy in stable patients undergoing additional hydration.

      In primary percutaneous intervention for infarction hydration is not possible. Therefore
      Acetylcystein might prevent contrast dye induced nephropathy.

      Furthermore, it might reduce infarct size as a result of its antioxidant properties.

      Clinical trials are missing so far examining the effects of Acetylcystein on nephropathy and
      infarct size.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial salvage measured by magnetic resonance imaging</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>prevention of nephropathy</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ST-segment resolution</measure>
    <time_frame>90 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI flow</measure>
    <time_frame>minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite clinical endpoint (death, reinfarction, congestive heart failure)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for dialysis</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microvascular obstruction measured by magnetic resonance</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infarct size measured by magnetic resonance</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxidative stress</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-dose N-Acetylcystein during percutaneous coronary intervention and for 2 days post intervention 2 x/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (NaCl)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylcystein</intervention_name>
    <description>high-dose N-Acetylcystein during PCI and for 2/day for 2 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>NaCl as placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ST-elevation infarction (&lt;12 hours)

          -  Angina

        Exclusion Criteria:

          -  Prior fibrinolysis

          -  Dialysis

          -  Pregnancy

          -  Lactase-reduction

          -  Glucose-galactose malabsorption

          -  Known allergy to acetylcystein
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger Thiele, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Heartcenter Leipzig GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Leipzig - Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2007</study_first_posted>
  <last_update_submitted>July 7, 2008</last_update_submitted>
  <last_update_submitted_qc>July 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Holger Thiele, MD</name_title>
    <organization>University of Leipzig - Heart Center</organization>
  </responsible_party>
  <keyword>primary PCI</keyword>
  <keyword>nephropathy</keyword>
  <keyword>infarct size</keyword>
  <keyword>infarction</keyword>
  <keyword>ST-elevation myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

